Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00256191
Status:
COMPLETED
Last Update Posted:
2007-10-15
First Post:
2005-11-16
Brief Title:
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Sponsor:
Cortice Biosciences Inc
Organization:
Cortice Biosciences Inc
Study Overview
Official Title:
A Phase 1 Open-Label Q21 Day Dose Escalation Multi-Center Study of TPI 287 in Patients With Advanced Malignancies
Status:
COMPLETED
Status Verified Date:
2005-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tapestry Pharmaceuticals Inc has developed a novel taxane analog TPI 287 TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material The synthesis involves modification to the taxane side chain to overcome multidrug resistance and to achieve mutant tubulin binding This study will be a multi-center dose escalation sequential group Phase 1 study evaluating the intravenous administration of TPI 287 on an every 21 day cycle
Detailed Description:
The primary objective of this study is to determine the maximum tolerated dose of TPI 287 administered every 21 days for Phase II clinical trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None